PDT is an effective adjuvant therapy for image-guided surgery in prostate cancer 181, demonstrating that the prostate-specific membrane antigen (PSMA)-targeted PDT agent PSMA-1-Pc413 selectively highlights PSMA-expressing tumors, allowing IGS and more complete tumor resection compared with white light surgery. This evidence concerns the gene FOLH1 and neoplasm.